SEC Form 4 · accession 0000905148-26-003838
Acrivon Therapeutics, Inc. · ACRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erick Gamelin
Officer — Chief Development Officer
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 4:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001781174
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 18, 2026 | S | 400 | $2.01 | D | 52,592 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.